Abstract

Autoimmune thyroid diseases (AITD) arise from complex interactions between genetic, epigenetic, and environmental factors. Whole genome linkage scans and association studies have established thyroglobulin (TG) as a major AITD susceptibility gene. However, the causative TG variants and the pathogenic mechanisms are unknown. Here, we describe a genetic/epigenetic mechanism by which a newly identified TG promoter single-nucleotide polymorphism (SNP) variant predisposes to AITD. Sequencing analyses followed by case control and family-based association studies identified an SNP (-1623A→G) that was associated with AITD in the Caucasian population (p = 0.006). We show that the nucleotide substitution introduced by SNP (-1623A/G) modified a binding site for interferon regulatory factor-1 (IRF-1), a major interferon-induced transcription factor. Using chromatin immunoprecipitation, we demonstrated that IRF-1 binds to the 5' TG promoter motif, and the transcription factor binding correlates with active chromatin structure and is marked by enrichment of mono-methylated Lys-4 residue of histone H3, a signature of active transcriptional enhancers. Using reporter mutations and siRNA approaches, we demonstrate that the disease-associated allele (G) conferred increased TG promoter activity through IRF-1 binding. Finally, treatment of thyroid cells with interferon α, a known trigger of AITD, increased TG promoter activity only when it interacted with the disease-associated variant through IRF-1 binding. These results reveal a new mechanism of interaction between environmental (IFNα) and genetic (TG) factors to trigger AITD.

Highlights

  • Autoimmune thyroid diseases (AITD) arise from complex interactions between genetic, epigenetic, and environmental factors

  • We demonstrated that interferon regulatory factor-1 (IRF-1) binds to the 5؅ TG promoter motif, and the transcription factor binding correlates with active chromatin structure and is marked by enrichment of mono-methylated Lys-4 residue of histone H3, a signature of active transcriptional enhancers

  • A number of TG variants have been reported to be associated with AITD, the causative variant or variants and the mechanisms by which these polymorphisms contribute to the complex etiology of AITD are not known

Read more

Summary

Patients and Controls

The project was approved by the Mount Sinai School of Medicine Institutional Review Board. We studied 271 Caucasian AITD patients, 201 with GD and 70 with HT. 165 age- and sex-matched healthy Caucasian individuals were used as controls in the association studies. Diagnosis of GD was based on the following: (i) documented clinical and biochemical hyperthyroidism requiring treatment with or without goiter; and (ii) presence of TSHR Abs and/or diffuse thyroid scan. HT was diagnosed by the presence of clinical and biochemical hypothyroidism requiring thyroid hormone replacement with or without goiter and by the presence of anti-thyroid peroxidase Abs, with or without anti-TG Abs. Control individuals had no personal or family history of thyroid disease, had normal thyroid functions, and were negative for thyroid autoantibodies

AITD Families
Case Control Association Analyses
Molecular Studies
Chromatin Immunoprecipitation
Luciferase Reporter Constructs
RESULTS
Cell line name
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call